Licorice: a sweet alternative to prevent hyperkalemia in dialysis patients?
In patients on hemodialysis, Farese et al. report that inhibition of the enzyme 11beta-hydroxysteroid dehydrogenase type 2 by glycyrrhetinic acid, the active compound of licorice, reduces serum potassium concentration and the frequency of hyperkalemia, possibly by enhancing intestinal potassium loss. This finding could be an important tool to maintain predialysis [K(+)] within safe limits in some dialysis patients at risk of hyperkalemic arrhythmias.
Ferrari
Paolo
P
Department of Nephrology, Fremantle Hospital, University of Western Australia, Perth, Australia. paolo.ferrari@health.wa.gov.au
D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D003348:Cortisone / Q000097:blood; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005527:Food, Fortified; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D006035:Glycyrrhiza; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006947:Hyperkalemia / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D011188:Potassium / Q000097:blood / Q000652:urine; D006435:Renal Dialysis / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D004791:Enzyme Inhibitors; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2; C468387:HSD11B2 protein, human; D006034:Glycyrrhetinic Acid; D011188:Potassium; D003348:Cortisone; D006854:Hydrocortisone